Results 111 to 120 of about 28,272 (264)

Beyond lipids: Systemic effects of lipoprotein apheresis

Transfusion, EarlyView.
Menatalla Nadim, Yamac Akgun
wiley   +1 more source

Long non‐coding RNA lncAPAT promotes atherosclerotic plaque instability by targeting ribosomal protein L22

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
LncAPAT interacted with the promoter region of RPL22 to inhibit RPL22 transcriptional activity and increase the expression of MCP‐1, thereby contributing to plaque instability. Abstract Background Long non‐coding RNAs (lncRNAs) regulate macrophage inflammation and atherosclerotic plaque stability, but mechanisms need comprehensive investigations ...
Rongxia Li, Qiyue Zhang, Yu Chen, Shuting Wang, Shuang Han, Adalaiti Kamili, Yixuan Zhong, Shujun Yang, Weili Zhang   +8 more
wiley   +1 more source

Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice

Journal of Lipid Research, 2012
Successful development of drugs against novel targets crucially depends on reliable identification of the activity of the target gene product in vivo and a clear demonstration of its specific functional role for disease development.
Elena Fattori, Manuela Cappelletti, Paola Lo Surdo, Alessandra Calzetta, Claus Bendtsen, Yan G. Ni, Shilpa Pandit, Ayesha Sitlani, Giuseppe Mesiti, Andrea Carfí, Paolo Monaci   +10 more
doaj   +1 more source

Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

, 2021
Benjamin J. Tombling, Carmen Lammi, Carlotta Bollati, Anna Anoldi, David J. Craik, Conan K. Wang   +5 more
openalex   +2 more sources

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes “DAMP” [PDF]

Circulation, 2021
openaire   +2 more sources

Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines

Cell Reports Medicine
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a therapeutic target for dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Two recent studies published by Fang et al.1 and Zhang et al.2 in Cell Reports Medicine and Cell Reports ...
Amirhossein Sahebkar, Maciej Banach
doaj   +1 more source

Intrinsic Motivation [PDF]

, 2014
Employs a literature review to describe intrinsic motivation as the force behind pro-social behavior, or when individuals willingly engage in behavior that is costly to them but benefits others.
Brock, J. Michelle, Leonard, Kenneth L., Serneels, Pieter   +2 more
core   +1 more source

Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3

JIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Persistent chylomicronemia is associated with severe hypertriglyceridemia (sHTG) and plasma triglycerides (TG) levels sustainably > 10 mmol/L (880 mg/dL) despite lipid lowering therapies. The main risk of persistent chylomicronemia is acute pancreatitis (AP). During the second and third trimester of pregnancy, TG levels significantly increase,
Miriam Larouche, Diane Brisson, Nathalie Roy, Claudy Grenon, Paul Poirier, Ma'an Muhsin, Daniel Gaudet   +6 more
wiley   +1 more source

Proprotein Convertase Subtilisin/kexin Type 9 Links Inflammation to Vascular Endothelial Cell Dysfunction [PDF]

, 2021
Thorsten M. Leucker, Nuria Amat-Codina, Stephen P. Chelko, Gary Gerstenblith   +3 more
openalex   +3 more sources

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

Journal of Lipid Research, 2010
Proprotein convertase, subtilisin/kexin type 9 (PCSK9), a key regulator of plasma LDL-cholesterol (LDL-c) and cardiovascular risk, is produced in liver and secreted into plasma where it binds hepatic LDL receptors (LDLR), leading to their degradation ...
Jeffrey D. Browning, Jay D. Horton
doaj   +1 more source